it is not medical advice , not a dosing recommendation, and AHK-Cu is not approved by the FDA for any use
The rate of change during this phase depends heavily on baseline body composition, caloric intake, activity level, and adherence to protocol
What they found: Dose-dependent stimulation of type II collagen (up to 2.5 baseline at 100 nM) Stimulation of aggrecan (up to 1.8 baseline) Inhibition of MMP-13 by ~40 % Partial protection against IL-1-induced matrix degradation Why it matters: It opened a completely new research area for AOD-9604 beyond lipolysis
Low price vs other metabolic peptides , shorter synthesis, smaller molecule
When NNMT is active, it slows fat breakdown, making your body use energy less efficiently
AHK-Cu, by contrast, is entirely synthetic